Reform of OTC distribution in Korea

Article information

J Korean Med Assoc. 2012;55(9):843-851
Publication date (electronic) : 2012 September 20
doi : https://doi.org/10.5124/jkma.2012.55.9.843
1Department of Social Medicine, Dankook University College of Medicine, Cheonan, Korea.
2Korean Academy of Medical Sciences, Seoul, Korea.
Corresponding author: Hyoung Wook Park, hywopark@gmail.com
Received 2012 August 20; Accepted 2012 August 30.

Abstract

In the US, over-the-counter (OTC) drugs have long been available in non-pharmacy outlets, and in the UK, general sale list medicines can be supplied without the need for the supervision of a pharmacist. Recently, the Japanese government allowed medications for colds or fever and painkillers, which account for 95% of general pharmaceuticals, to be sold at retail stores through the amendment to the Pharmaceutical Affairs Act. Among the key trends of the global OTC market are major changes in product distribution. However, in Korea, the independent pharmacy model traditionally has been the method of OTC distribution for many years. 19 years have passed since the first civil petition for non-pharmacy distribution of selected OTC drugs. At last in 2012, Korea revised the Pharmaceutical Affairs Act, allowing selected non-prescription drugs to be distributed by non-pharmacy outlets. The revised Pharmaceutical Affairs Act restricted the number of selected OTC drugs to under 20. The new Act included the registrations of nonpharmacy outlets and the mandatory education of the sellers. We must discuss the criteria for placement of medicines on the GSL, the reclassification system based on the safety profile of the medicines, and the expansion of non-pharmacy outlets. In preparation for the aged society, we should implement health policies to lower the price of pharmaceuticals by adopting the market principle thus giving consumers a broader choice.

References

1. Editorial. How long are we going to block OTC sales in retail stores? The Hankook Ilbo 2010. 12. 24.
2. Tisman A. The rising tide of OTC in Europe [Internet] 2010. cited 2012 Aug 27. Parsippany: IMS Health; Available from: http://www.imshealth.com/deployedfiles/ims/Global/Content/Solutions/Healthcare%20Measurement/Consumer%20Health%20Insights/The_Rising_Tide_Of_OTC_Europe.pdf.
3. . Pharmaceutical distribution in central Europe in 2011: liberalization of non-pharmacy and online sales [Internet] 2011. cited 2012 Aug 27. Krakow: PMR Publications; Available from: http://www.pmrpublications.com/press-releases/251/pharma-ceutical-distribution-in-central-europe-in-2011-liberalisation-of-non-pharmacy-and-online-sales.
4. Macarthur D. . European pharmaceutical distribution: key players, challenges and future strategies [Internet] 2007. cited 2012 Aug 27. London: Informa UK Ltd.; Available from: http://www.scripintelligence.com/home/European-Pharmaceutical-Distribution-Key-Players-Challenges-and-Future-Strategies-2034.
5. Dudley JW. OTC distribution in Europe 2010. Worcestershire: James Dudley International Ltd;
6. The Medicines Act 1968 [Internet] cited 2012 Aug 27. Surrey: The National Archives; Available from: http://www.legislation.gov.uk/ukpga/1968/67/contents.
7. Legal status and reclassification: MHRA [Internet] cited 2012 Aug 27. London: The Medicines and Healthcare products Regulatory Agency; Available from: http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Legalstatusandreclassification/index.htm.
8. The Human Medicines Regulations 2012 No. 1916: regulation 62 (3) [Internet] cited 2012 Aug 27. Surrey: The National Archives; Available from: http://www.legislation.gov.uk/uksi/2012/1916/regulation/62/made.
9. The Human Medicines Regulations 2012 No. 1916: regulation 62 (5) [Internet] cited 2012 Aug 27. Surrey: The National Archives; Available from: http://www.legislation.gov.uk/uksi/2012/1916/regulation/62/made.
10. MHRA guidance: how to change the legal classification of a medicine in the UK [Internet] cited 2012 Aug 27. London: The Medicines and Healthcare products Regulatory Agency; Available from: http://www.mhra.gov.uk/home/groups/commsic/documents/publication/con172237.pdf.
11. Brass EP, Lofstedt R, Renn O. Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment. Clin Pharmacol Ther 2011. 90791–803.
12. Domestic and international cases of improvement in regulations concerning general pharmaceuticals 2009. Seoul: Korea Chamber of Commerce and Industry;
13. Suggestions for OTC sales in convenience stores. Yonhap News 1993. 08. 13.
14. Chae SS. Classification of prescription, pharmacy, and retail store drugs. Yonhap News 1998. 05. 20.
15. Song SG. OTC sales in retail stores expected this year. The Dong-A Ilbo 2003. 01. 22.
16. Jung MS. Debate about selling antacids and analgesics in retail stores. The Hankook Ilbo 2007. 06. 26.
17. Lim HJ. Conflicts between Ministry of Finance and Ministry of Health & Welfare concerning health and pharmaceutical policy reform. Yonhap News 2009. 12. 15.
18. Yonhap Opinion. Drug sales outside the pharmacy? Yonhap News 2011. 01. 09.
19. Article 44-2 (1) of Pharmaceutical Affairs Act 2012. 05. 14.
20. Article 107-1, 2 of Enforcement Rule of Pharmaceutical Affairs Act 2012. 05. 14.
21. Article 44-2 (2) of Pharmaceutical Affairs Act 2012. 05. 14.
22. Article 108 of Enforcement Rule of Pharmaceutical Affairs Act 2012. 05. 14.
23. Article 76-3 (1) of Pharmaceutical Affairs Act 2012. 05. 14.
24. Article 113-1 of Enforcement Rule of Pharmaceutical Affairs Act 2012. 05. 14.
25. Article 44-4 of Pharmaceutical Affairs Act 2012. 05. 14.
26. Article 116-1 of Enforcement Rule of Pharmaceutical Affairs Act 2012. 05. 14.
27. Lee EP. Up to 4000 cases of side effects reported from generic drugs in the last 5 years. Yonhap News 2011. 09. 15.

Article information Continued